Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Growth Rates · Payout · Yield
Dividends Over Time
Growth Rates · Payout · Yield
Growth Rates
%
YoY
%
3Yr
%
5Yr
%
10Yr
Key Metrics
- -%
TTM Yield
- -
Average Days Gap
Series
% - -
Yield
0.00%
Payout Ratio
History
We could not find any dividend history for Solid Biosciences Inc..